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Introduction
　Cisplatin is one of the most widely used drugs as part of 
a combination chemotherapeutic regimen for treating lung 
cancer and other solid tumors. Chemotherapy with cyto-
toxic agents plays an important role in the treatment of lung 
cancer. Several trials have documented the efficacy of adju-
vant cisplatin-based chemotherapy (1, 2) ; therefore, the ten-
dency has been increasing for chemotherapy to be used as 
adjuvant therapy after surgery. 
　Cisplatin demonstrates an anti-tumor reaction that binds 
the drug to DNA and creates platinum–DNA adducts. Al-
though cisplatin produces a good anti-tumor reaction, it is 
well known for producing severe adverse events such as re-
nal dysfunction, vomiting, etc. To treat chemotherapy-in-
duced nausea and vomiting (CINV), various anti-emetic 
drugs have been developed, such as 5-hydroxytryptamine 
type 3 (5-HT3) receptor antagonists (3) and neurokinin-1 re-
ceptor antagonists (4). Antiemetic guidelines were estab-
lished, and the control of CINV was improved.
　To prevent renal dysfunction caused by cisplatin, hydra-
tion and evaluation of renal function before chemotherapy 
have been recommended (5). In addition, monitoring of the 
magnesium level and routine magnesium supplementation 
have also been recommended (6, 7). Some reports have indi-
cated that the administration of magnesium before adminis-
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tration of cisplatin prevents the development of renal dys-
function (8, 9).
　Recently, some indicate the possibility that the renal dys-
function after high-dose cisplatin-based chemotherapy can 
be prevented by a short hydration regimen that includes 
magnesium (10). However, previous studies have not provid-
ed sufficient evidence regarding the prevention of renal dys-
function because the clinical trials were small and not aimed 
at treating thoracic tumors (8,  9). Therefore, the purpose of 
the present study was to survey the efficacy of magnesium 
in preventing renal disfunction after administration of high-
dose cisplatin for treatment of thoracic tumors.
Method and patients
Patients and treatment
　Information was collected on patients who had been 
pathologically diagnosed with thoracic malignancies and 
treated with cisplatin-based chemotherapy as first-line ther-
apy between May 2008 and June 2013 at Nagasaki Univer-
sity School of Medicine and Japanese Red-Cross Nagasaki 
Atomic Bomb Hospital. All patients were administered cis-
platin at a dose of more than 50 mg/m2 in each cycle, and 
received sufficient hydration and antiemetic agents. The fol-
lowing variables before treatment were collected: sex, age, 
weight, body surface area, performance status (PS) accord-
ing to the Eastern Cooperative Oncology Group scale, path-
ological type of cancer, and clinical staging. Serum creati-
nine level and estimated glomerular filtration rate according 
to the Japanese Society of Nephrology (eGFR) were ob-
tained just before each chemotherapy cycle. In accordance 
with the previous report (10), we defined the patients who 
were intravenously administered magnesium at a dose of ≥ 
8 mEq during the chemotherapy as the study group, and 
defined the patients who did not receive magnesium or who 
were intravenously administered magnesium at a dose of < 
8 mEq during the chemotherapy as the control group. The 
study protocol was reviewed and approved by the institu-
tional review board. 
Renal function
　The evaluation of renal function in each patient was per-
formed by estimating the serum creatinine level and eGFR. 
We used eGFR because it has come to be recognized as the 
most accurate eGFR in Japanese cancer patients. In Japan, 
the eGFR is calculated using the Cockcroft–Gault formula, 
creatinine clearance measured by 24-h urine collection, the 
0.808 × Modification of Diet in Renal Disease study equa-
tion, and the 0.813 × Chronic Kidney Disease Epidemiol-
ogy Collaboration equation (11). 
The eGFR formula is as follows: 
eGFR (ml/min/ 1.73 m2) = 194 × (serum creatinine)-1.094 × 
(age)-0.287 (× 0.739 if female) (12). We defined elevation of se-
rum creatinine level as higher than the institutional upper 
limit of the normal level, and low serum creatinine level as 
lower than the institutional lower limit of the normal level. 
Statistical analysis
　Differences between the study group and the control 
group were evaluated using the chi-square test. In this anal-
ysis, renal dysfunction was defined as elevation of serum 
creatinine level beyond the upper limit of the institutions. 
Additional hydration due to renal dysfunction was also 
evaluated using the chi-square test. Relationships between 
renal dysfunction and various parameters were evaluated by 
the Mann–Whitney U test and the chi-square test. In multi-
variate analysis, we used the logistic regression method. 
Statistical significance was determined by using two-tailed 
P values and was reported at P < 0.05. All of the statistical 
analyses were performed using SPSS (SPSS for Windows, 
version 22.0, SPSS, Chicago, IL, USA).
Results
Patients
　Data was analyzed for 146 patients who were treated be-
tween June 2008 and June 2013. There were 77 patients who 
were treated with platinum-based chemotherapy without 
magnesium (control group), and 69 patients who received 
magnesium (study group). Table 1 shows the characteristics 
of both groups. There were no significant differences be-
tween both groups in terms of age, sex, and PS. Eight pa-
tients with malignant pleural mesothelioma (MPM) were 
treated with magnesium-containing regimens, and 8 pa-
tients with MPM were treated with magnesium-free regi-
mens. No patients with thymic tumors were treated with 
magnesium-containing regimens, and 6 patients with thy-
mic tumors were treated with regimens containing magne-
sium of doses < 8 mEq. There was no statistically signifi-
cant difference in the serum creatinine and eGFR just before 
the administration of cisplatin-containing regimens.
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Treatment
　A total of 394 treatments were evaluated in the analysis 
of the present study: 193 treatments in the study group and 
201 treatments in the control group. The median number of 
chemotherapy cycles was 3 in both groups. Seventeen pa-
tients (23%) in the control group and 23 patients (31%) in the 
study group received more than 4 cycles. The mean dose of 
cisplatin in the study group and the control group was 68.3 
mg/m2 and 70.9 mg/m2, respectively (P = 0.1105). In the 
control group, irinotecan, etoposide and gemcitabine were 
mainly used with cisplatin. In the study group, pemetrexed, 
S-1 and vinorelbine were the main drugs that were used. 
The frequency of combined thoracic radiotherapy was 22% 
and 17% in the control and study group, respectively. 
Renal function
　Figure 1 shows the fluctuations in serum creatinine and 
eGFR just before each treatment. The mean serum creati-
nine level and mean eGFR for all cycles were stable at 
around 0.8 mg/dl and 80 ml/min/1.73m2 in both groups. Fig-
ure 1 also indicates that the elevation of serum creatinine 
and the reduction of eGFR were mild in the study group 
compared with the control group after three cycles, although 
this observation was not statistically significant.
　In the 394 treatments, 77 treatments produced an eleva-
tion in serum creatinine (19.5%). Of these, 24 (12.4%) were 
in the control group (n = 193), and 53 (26.3%) were in the 
study group (n = 201); this difference was statistically sig-
nificant (P = 0.006). In other parameters, the serum creati-
nine level and eGFR level before treatment and patient age 
were statistically associated with elevation in serum creati-
nine (Table 2). In multivariate analysis, magnesium and 
eGFR before treatment were found to be statistically sig-
nificant, but the other parameters were not statistically sig-
nificant (Table 3). 
　Additional infusions to protect renal function were ad-
ministered in a total of 35 treatments (8.9%); 21 treatments 
in the control group and 14 in the study group, with no sta-
tistically significant differences. In addition, there were no 
grade 3 or 4 neuromuscular or cardiovascular adverse events 
recorded in either group that might have been related to hy-
permagnesemia, although the serum magnesium level had 
failed to be checked in most treatments.
　Eight patients (10.4%) in the control group and 4 patients 
(5.7%) in the study group did not experience recovery of 
renal dysfunction. Seven patients (9.1%) in the control group 
Table 1. Patient characteristics and renal function before cisplatin-based chemotherapy
　Characteristics Non-Mg  Mg P value
Age (n), Median (range)
Men : Women (n)
Performance Status (n) 0：1：2  
Disease (n)
NCSLC
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NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; MPM, malignant pleural mesothelioma; Cr, serum creatinine; eGFR, estimated 
glomerular filtration rate.
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Table 3. Result of multivariate analysis of risk factors for the elevation of serum creatinine level 
caused by cisplatin

















　Mg, magnesium; Cr, serum creatinine; eGFR, estimated glomerular filtration rate.
and four patients (5.7%) in the study group required dosage 
reduction of cisplatin. Neither the recovery of renal function 
nor dosage reduction of displatin were statistically signifi-
cant between the study group and the control group.
Discussion
　The results of this analysis support that renal dysfunction 
induced by a cisplatin-based chemotherapeutic regimen 
might be prevented by the intravenous infusion of magne-
sium before the administration of cisplatin. Recently, Yoshi-
da et al. (13) retrospectively analyzed the role of magnesium 
in patients with thoracic malignancy who were treated with 
cisplatin-based combination chemotherapy. According to 
this report, the elevation of serum creatinine in the magne-
sium group was significantly lower during all cycles than in 
the non-magnesium group, and, in a multivariate analysis, 
magnesium preloading significantly reduced cisplatin-in-
duced nephrotoxicity throughout the entire period from af-
ter the first administration. The investigators concluded that 
magnesium preloading before cisplatin administration sig-
nificantly reduced cisplatin-induced nephrotoxicity. The re-
sults of the present study also indicate that magnesium pre-
loading significantly prevented the elevation of serum 
creatinine levels. 
　Measurement of eGFR is a new method for estimating 
the glomerular filtration rate in the Japanese population (14). 
This method can evaluate the glomerular filtration rate ex-
actly according to age, sex, and serum creatinine levels 
without measuring the amount of urine creatinine. Thus, 
eGFR can evaluate renal function exactly even after the ad-
ministration of cisplatin. In the present study, we evaluate 
the eGFR just before each cycle of cisplatin. Although not 
statistically significant, the reduction in eGFR was mild in 
the magnesium-preloading group compared with the non-
magnesium-preloading group after three chemotherapy cy-
cles (Fig 1). This led to the hypothesis that magnesium pre-
loading might prevent renal dysfunction induced by 
repeated administrations of cisplatin. 
　The present retrospective analysis regarding the preven-
tion of renal dysfunction induced by cisplatin by magne-
Table 2. Result of univariate analysis of risk factors for the elevation of serum creatinine level caused by cisplatin
　Factors Above normal level  Within normal level P value
Cr (mg/dl), Mean ± SD
eGFR (ml/min/ 1.73 m2), 
Mean ± SD
Age, Median (range)
Men : Women (n)
Body surface area (m2), 
Mean ± SD




















　Mg, magnesium; Cr, serum creatinine; eGFR, estimated glomerular filtration rate.
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sium preloading had some limitations. First, the method for 
determing eGFR has only been established relatively re-
cently; therefore, few prospective analyses have been con-
ducted that evaluate the relationship between eGFR and 
cisplatin-induced renal dysfunction. Second, we could not 
evaluate the timing and dose of magnesium preloading. On 
these two points, a further prospective trial is needed to 
evaluate the relationship between eGFR and cisplatin-in-
duced renal dysfunction, and the adequate timing and dose 
of magnesium preloading.    
　In conclusion, the present study retrospectively revealed 
that intravenous administration of magnesium prevented 
elevation in the serum creatinine level in patients with tho-
racic tumor treated with cisplatin-containing regimens. 
This suggests that administration of magnesium might re-
duce nephrotoxicity caused by cisplatin. Although few pro-
spective trials exist, and adequate dosing and timing re-
mains unclear, magnesium might be considerably useful in 
cisplatin-based chemotherapy for patients with non-small 
cell lung cancer. Further investigations are needed to con-
firm that magnesium preloading prevents nephrotoxicity, 





























Non-Mg (n) 75 58 38 17 4 2
Mg (n) 69 55 36 23 6 4
Cycle
Figure 1
Fig.1 Graphs showing the fluctuations of the level of serum creatinine (Cr) and estimated glomerular 
filtration rate (eGFR) just before each treatment. The red line indicates the magnesium-preloading 
group (Mg), and the blue line indicates the magnesium non-preloading group (Non-Mg).
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